Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

Ashique Rafique

Tammy T Huang

Sean Stevens

Nicholas J Papadopoulos

Joel H Martin

Jeanette L Fairhurst

Kevin J Pobursky

Eric L Smith

Margaret Karow

Gang Chen

James P Fandl

Ergang Shi

Allen Radin

Joan A Windsor

Warren R Mikulka

Raymond W Leidich

Diana M Ahrens

Marcela Torres

Gavin Thurston

Jessica Kirshner

Lauric Haber

Alison Crawford

Drew Dudgeon

Eric B Smith

Andrew J Murphy

Lynn Macdonald

Samuel H Davis

Neil E Stahl

Robert Babb

Lori C Morton

Supriya Patel

Michael E Dunn

Vishal Kamat

Ishita Chatterjee

Jessica R Kirshner

Eric Smith

The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

The present disclosure provides novel immunoglobulin proteins that bind to a human natriuretic peptide receptor 1 (NPR1) agonist, preferably an anti-NPR1 antibody. In certain embodiments, the proteins of the disclosure comprise at least one immunoglobulin variable domain that binds to an anti-NPR1 antibody. In certain embodiments, the proteins of the disclosure are useful in blocking and/or reversing the effect of an administered anti-NPR1 antibody. In certain embodiments, the antigen-binding proteins are useful for effective management of blood pressure and hemodynamics in humans.

Immunoglobulin proteins that bind to NPR1 agonists

A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a Kof about 500 pM or less and blocks IL-6 activity with an ICof 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

High affinity antibodies to human IL-6 receptor

Methods for making, identifying, isolating and/or making binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Exemplary binding proteins specific to small molecules are also provided.

Vantigen binding proteins exhibiting distinct binding characteristics

Nucleic acids encoding high affinity antibodies to human IL-6 receptor

The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R&#x3b1;) with an affinity constant (K) of less than 200 pM, as measured by surface plasmon resonance, is provided.

High affinity human antibodies to human IL-4 receptor

The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.

Method of treating rheumatoid arthritis with an IL-6R antibody

Growing community of inventors

Yonkers, NY, United States of America

Ashique Rafique